Trial Profile
Phase I Trial of the Combination of Ibrutinib and Lenalidomide for the Treatment of Patients With MDS Who Have Failed or Refuse Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 11 Oct 2021 Status changed from active, no longer recruiting to completed.
- 26 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 Sep 2021.
- 26 Apr 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Sep 2021.